Abstract
Neuroendocrine tumors (NET), especially those of the pancreas and gastrointestinal tract, are frequently metastatic at the time of initial diagnosis. Because of a better knowledge of the molecular and cell-biological aspects as well as the clear pathological characterization of this tumor entity, a worldwide overall increase of these neuroendocrine tumors is reported. Therapeutic approaches for management of metastatic disease include surgical, medical, radiological, and nuclear medicine strategies. We present our experiences of management of three clinical cases of ileum, rectum, and gastric metastatic neuroendocrine tumors treated at the ENETS Center for Neuroendocrine Tumors of Naples, Italy. In the case of ileum-NET, we demonstrate the potent antiproliferative effect of SSA and the decisive role of the multidisciplinary approach which is able by itself to impact on survival. Then, in the case of gastric NET, we stress such awful consequences; a late and misunderstood diagnosis may have on prognosis and on the quality of life of a young patient. The role of a center of excellence devoted to NETs becomes crucial in these situations. Regarding the last case, it is a patient with G2 rectum NET. His clinical history, characterized by successive progressions of disease, is a paradigm of the G2 metastatic neuroendocrine tumors treatment. Three lines of therapy (SSA, chemotherapy, and PRRT) have followed ensuring a prolongation of survival of the patient and a good quality of life. The patient is in follow-up and maintains additional therapeutic chance.
On behalf of the ENETS Center of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples, Italy
This is a preview of subscription content, log in via an institution to check access.
Bibliography
Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27(28):4656–4663
Caplin ME, Pavel DM, Ćwikła JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371(3):224–233
Yao JC, Tsuchihashi Z, Panneerselvam A et al (2011) Effect of everolimus treatment on markers angiogenesis in patients with advanced pancreatic neuroendocrine tumours (pNET) results from the phase III RADIANT-3 study. Eur J Cancer 47(Suppl. 1)
Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Fourth Trial (RADIANT-4) Study Group. Lancet 387(10022):968–977. doi:10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17
Lahner H, Rinke A, Unger N et al (2016) Sunitinib efficacy in patients with advanced pNET in clinical practice. Horm Met Res 48(9):575–580
Moertel CG, Kvols LK, O’Connell MJ et al (1991) Treatment of neuro-endocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Abstr US Endocr Soc 68:227–232
Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406
Ekeblad S, Sundin A, Janson ET et al (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 15:2986–2991
Kulke M, Blaszkowsky LS, Zhu AX et al (2010) Phase I/ II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). 2010 ASCO gastrointestinal cancers symposium. Abstract No. 223
Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2):268–275
Fjallskog ML, Janson ET, Falkmer UG et al (2008) Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 88:53–58
Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523
Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-02. Abstract Number:7502, 2015 ASCO Annual Meeting
Nghiem PT, Bhatia S, Lipson EJ et al (2016) PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Eng J Med 374(26):2542– 2552
Delle Fave G et al (2012) ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 95:74–87
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Tafuto, S. et al. (2018). Therapy for Metastatic Disease: Stomach/Duodenum, Colon/Rectum. In: Colao, A., Faggiano, A., de Herder, W. (eds) Neuroendocrine Tumors in Real Life. Springer, Cham. https://doi.org/10.1007/978-3-319-59024-0_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-59024-0_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-59022-6
Online ISBN: 978-3-319-59024-0
eBook Packages: MedicineMedicine (R0)